Medidata Acorn AI Synthetic Control Arm® Named “Best AI-based Solution for Healthcare” by 2021 AI Breakthrough Awards – TechDecisions

Medidata’s Acorn AI Synthetic Control Arm (SCA) awarded Best AI-based Solution for Healthcare.

CONTEXT:  Medidata’s Acorn AI Synthetic Control Arm (SCA) takes Best AI-based Solution for Healthcare at this years AI Breakthrough Awards.  Selected from more than 2,200 nominations, Acorn is a type of external control arm that is generated using patient-level data from individuals external to a trial.  Due to Medidata’s unique pool of over 7 million anonymised patient records, they are the only external control group provider with cross-industry historical clinical trial data.   READ TIME:  1 min 1. “Due to Medidata’s unique pool of more than seven million anonymized patient records, Medidata SCA offers the only external control group created with cross-industry historical clinical trial data.”  2. “SCA can make certain randomized controlled trials more attractive to patients, and reduce recruitment and retention challenges. NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Systemes company, today announced that the Medidata Acorn AI Synthetic Control Arm® (SCA) has been awarded “Best AI-based Solution for Healthcare” in this year’s AI Breakthrough Awards.”  3. “Amid a crowded AI market and during the COVID-19 pandemic, Medidata has changed the world of clinical trials through its unique approach to external controls—the Medidata SCA.”  4. ““Because patients who are seeking treatment through a clinical trial have often already considered standard-of-care treatments and found them unappealing, many view an investigational drug as an opportunity for something better, particularly with rare and life-threatening diseases,” said Arnaub Chatterjee, senior vice president, Medidata Acorn AI Product & Ecosystem.”  5. “In a precedent setting acceptance of a hybrid external control (combining synthetic control arm patients with randomized patients), the U.S. Food and Drug Administration (FDA) recently authorized a phase 3 registrational trial (one to be used for a potential new drug submission) using this breakthrough innovation.”  Source URL: https://mytechdecisions.com/latest-news/medidata-acorn-ai-synthetic-control-arm-named-best-ai-based-solution-for-healthcare-by-2021-ai-breakthrough-awards/